Lomibuvir (VX-222, VCH-222) is a potent and selective, nonnucleoside inhibitor of HCV NS5B polymerase inhibitor with Kd of 17 nM.
Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with EC50 of 17 nM, the M423I and A486S variants remaine susceptible to VX-222.
Lomibuvir exhibits non-competitive and selective inhibition in HCV NS5B of genotype 1a and 1b, with IC50 of 0.94 and 1.2 uM, respectively.
Lomibuvir displays fine pharmacokinetic profile in rats and dogs.
